Heparin therapy. Regimens and treatment considerations

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Heparin is a parenteral antithrombotic agent.
• It is effective in treating and preventing venous thromboembolic disease and preinfarctional angina.
• Evidence suggests heparin's utility in preventing coronary artery reocclusion post-thrombolytic therapy for acute myocardial infarction and left ventricular mural thrombosis.

Purpose of the Study:

• To review the efficacy and dosing of heparin in various thrombotic conditions.
• To outline appropriate heparin administration for different patient risk levels and clinical scenarios.
• To discuss heparin's role in acute myocardial infarction and venous thromboembolism prevention and treatment.

Main Methods:

• Review of accumulating evidence on heparin's use.
• Analysis of dosing strategies for subcutaneous and intravenous administration.
• Consideration of monitoring parameters like activated partial thromboplastin time (aPTT).

Main Results:

• Heparin offers marginal mortality benefit when combined with thrombolytic therapy and aspirin for acute myocardial infarction.
• For moderate-risk venous thromboembolism prevention, 5000 U subcutaneously every 12 hours for 5-7 days is recommended.
• For high-risk patients (e.g., hip replacement), subcutaneous heparin aims to prolong aPTT by 4-5 seconds into the upper normal range.
• For active venous thromboembolism or peri-infarctional states, intravenous heparin infusion is used to prolong aPTT to 1.5-2.5 times the control value.
• Subcutaneous heparin every 12 hours is an alternative if IV infusion is not feasible, aiming for aPTT 1.5-2.5 times control.
• This regimen is also recommended for pregnant women with venous thromboembolic disease or mechanical heart valves.

Conclusions:

• Heparin is a crucial antithrombotic agent with varied applications.
• Dosing and administration routes (subcutaneous vs. intravenous) should be tailored to clinical indication and patient risk.
• Monitoring aPTT is essential for optimizing therapeutic efficacy and safety across different scenarios.